Drugs / DC50292A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07071090 | Jun 2025 → Jan 2028 expected | — | Heronova Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DC50292A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07071090 ↗ |
| Route | Oral | “All enrolled subjects will receive DC50292A orally” NCT07071090 ↗ |